Valneva surges after EU regulator validates Lyme disease vaccine application

PFE•2026-08-14

EU validation lifts Valneva shares

French vaccine maker Valneva VLS.PA jumps 15.6% after the European Medicines Agency validated the marketing application for its Lyme disease vaccine candidate, developed with partner Pfizer PFE.N.

The validation marks a key regulatory milestone for the Lyme programme, which Kempen analysts describe as "the key" driver of the investment case.

The broker had flagged a potential filing by Pfizer during H2 2026 as a critical near-term catalyst, with a possible U.S. approval decision expected in H2 2027.

Kempen notes that Pfizer's latest commentary "continues to signal optimism on the vaccine candidate's prospects of approval".

The shares are on track for their best day since August 2025 if the gains hold.

Valneva surges after EU regulator validates Lyme disease vaccine application

EU validation lifts Valneva shares

Related News

Williams-Sonoma Inc <WSM.N>: RBC Raises Target Price to $260 From $192

Nasdaq trade halt continues <MCTA.O> reason not available at 03:58 am

Valneva, Pfizer Lyme vaccine application clears EMA validation step

Heartflow, Inc. <HTFL.O>: Canaccord Genuity raises target price to $45 from $37

Tapestry, Inc. <TPR.N>: Jefferies cuts target price to $144 from $150